Common diabetes drug linked to better survival in melanoma patients

A new study finds that melanoma patients who take metformin for diabetes show improved survival rates compared to those who don't use the drug. The finding could reshape treatment strategies for the roughly 20% of melanoma patients with diabetes, potentially offering a low-cost intervention that extends life.

Originaltitel: Association of metformin use and survival in patients with cutaneous melanoma and diabetes